Bipartisan Lawmakers Push for MDMA Therapy for PTSD as FDA Decision Looms

LOS ANGELES- In a rare show of bipartisanship, 80 members of Congress have united to urge President Joe Biden and the FDA to prioritize research on MDMA-assisted therapy for treating post-traumatic stress disorder (PTSD). The initiative, which seeks to fast-track access to new treatment options, is driven by a rising veteran suicide crisis and the limitations of existing PTSD therapies.

The lawmakers’ letters come as the FDA prepares to rule on the potential approval of MDMA for PTSD treatment, a decision expected by August 11. This would mark a significant step in the broader acceptance of psychedelic-assisted therapies, which have gained momentum after years of skepticism.

Led by Michigan GOP Rep. Jack Bergman and Colorado Democrat Sen. Michael Bennet, the letters emphasize the urgent need for new, effective treatments as current options, such as antidepressants and cognitive behavioral therapy, fail to adequately address PTSD for many. Veterans have been particularly vocal in advocating for MDMA-assisted therapy, which has shown promise in clinical trials but still faces regulatory challenges.

While the FDA has raised concerns over the integrity of the data supporting MDMA’s efficacy and safety, the bipartisan push reflects growing support within both the veteran community and the broader public. The VA has already begun preparing for the possible rollout of MDMA therapy, pending FDA approval, as part of its efforts to tackle the ongoing veteran mental health crisis.

As the FDA decision nears, proponents argue that exploring innovative treatments like MDMA could be key to addressing a critical gap in PTSD care. The outcome could set a precedent for the future of psychedelic-assisted therapies in the U.S., potentially offering new hope for millions living with PTSD.